ATE397609T1 - Corticotropinfreisetzungsfaktor antagonisten - Google Patents

Corticotropinfreisetzungsfaktor antagonisten

Info

Publication number
ATE397609T1
ATE397609T1 AT02730487T AT02730487T ATE397609T1 AT E397609 T1 ATE397609 T1 AT E397609T1 AT 02730487 T AT02730487 T AT 02730487T AT 02730487 T AT02730487 T AT 02730487T AT E397609 T1 ATE397609 T1 AT E397609T1
Authority
AT
Austria
Prior art keywords
alkyl
halo
alkoxy
alkenyl
alkynyl
Prior art date
Application number
AT02730487T
Other languages
English (en)
Inventor
Fabio Romano Di
Chiara Marchionni
Fabrizio Micheli
Alessandra Pasquarello
Benedetta Perini
Yves St-Denis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0114343A external-priority patent/GB0114343D0/en
Priority claimed from GB0114349A external-priority patent/GB0114349D0/en
Priority claimed from GB0117399A external-priority patent/GB0117399D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE397609T1 publication Critical patent/ATE397609T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02730487T 2001-06-12 2002-06-11 Corticotropinfreisetzungsfaktor antagonisten ATE397609T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0114343A GB0114343D0 (en) 2001-06-12 2001-06-12 Chemical compounds
GB0114349A GB0114349D0 (en) 2001-06-12 2001-06-12 Chemical compounds
GB0117399A GB0117399D0 (en) 2001-07-17 2001-07-17 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE397609T1 true ATE397609T1 (de) 2008-06-15

Family

ID=27256186

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02730487T ATE397609T1 (de) 2001-06-12 2002-06-11 Corticotropinfreisetzungsfaktor antagonisten

Country Status (7)

Country Link
US (1) US7462622B2 (de)
EP (1) EP1395591B1 (de)
JP (1) JP2004533465A (de)
AT (1) ATE397609T1 (de)
DE (1) DE60226971D1 (de)
ES (1) ES2307750T3 (de)
WO (1) WO2002100863A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
JP2006525261A (ja) * 2003-05-05 2006-11-09 エフ.ホフマン−ラ ロシュ アーゲー Crf活性を有する縮合ピリミジン誘導体
JP4926720B2 (ja) * 2003-12-22 2012-05-09 スミスクライン ビーチャム (コーク) リミテッド Crf受容体アンタゴニストおよびそれらに関連する方法
JP2007526906A (ja) * 2004-03-05 2007-09-20 大正製薬株式会社 ピロロピリミジン誘導体
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
EP1802621B1 (de) * 2004-10-19 2009-05-06 SmithKline Beecham (Cork) Limited Crf-rezeptor-antagonisten und zugehörige verfahren
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
JP7357932B2 (ja) * 2018-04-09 2023-10-10 ラクオリア創薬株式会社 Crhr2拮抗薬としての縮合環状尿素誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022644D0 (en) 1990-10-18 1990-11-28 Ici Plc Heterocyclic compounds
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
JP2001514260A (ja) 1997-09-02 2001-09-11 デュポン ファーマシューティカルズ カンパニー Cnsおよびストレス関連疾患の治療に有用な、副腎皮質刺激ホルモン放出ホルモン拮抗剤としての、複素環基が置換した環縮合ピリジン類およびピリミジン類
AU2002253357B2 (en) 2001-04-30 2006-08-24 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US7462622B2 (en) 2008-12-09
EP1395591B1 (de) 2008-06-04
ES2307750T3 (es) 2008-12-01
US20050054661A1 (en) 2005-03-10
JP2004533465A (ja) 2004-11-04
DE60226971D1 (de) 2008-07-17
EP1395591A1 (de) 2004-03-10
WO2002100863A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
MXPA05010874A (es) Compuestos n-heterociclicos condensados y su uso como antagonistas del receptor del factor liberador de corticotropina.
ATE363473T1 (de) Substituierte pyrazoloverbindungen zur behandlung von entzündungen
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
WO2003008412A3 (en) Hetero-bicyclic crf antagonists
ZA200505273B (en) Novel compound
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
UA85502C2 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
DE60226971D1 (de) Corticotropinfreisetzungsfaktor antagonisten
MXPA04005157A (es) Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
AP1396A (en) 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives.
ZA200309942B (en) Chemical compounds.
GEP20032928B (en) Halo Derivatives of 9-Deoxo-9a-Aza-9a-Homerythromycin A, Method for its Production, Pharmaceutical Compositions Containing the Same and Their Use for Treatment or Prevention of Bacterial Infections
BR0209035A (pt) Antagonistas de receptor crf
ATE238995T1 (de) $g(a)-$g(a)' -substituierte n-alkyl-3- alkenylbenzoyl-pyrazol-derivate
SI1501823T1 (sl) Novi piperidinil-alkilamino-piridazinonski derivati, postopek za njihovo pripravo in farmacevtski sestavki, ki vsebujejo te spojine
MXPA02012072A (es) Derivados de 4,5-dihidro-tiazol-2-ilamina y su uso como inhibidores de no-sintasa.
YU79401A (sh) Derivati 1-trifluorometil-4-hidroksi-7-piperidinil- aminometilhromana

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties